Predictmedix Stock Price, News & Analysis

Predictmedix AI (OTC: PMEDF) closed the final tranche of a non-brokered private placement on December 5, 2025, issuing 3,050,000 Units at C$0.05 each for gross proceeds of $152,500, bringing total capital raised across all tranches to $612,650.

Each Unit includes one common share and one half warrant; each full Warrant allows purchase of one common share at C$0.15 for 36 months. Warrants may be accelerated if the CSE volume-weighted average share price equals or exceeds C$0.30 for 10 consecutive trading days after the four-month hold.

All securities are subject to a statutory hold of four months and one day. Management described the raise as selective and strategic, focused on investors who add operational value rather than maximizing capital.

Predictmedix AI (OTC: PMEDF) announced the closing of the first tranche of a non-brokered private placement on November 17, 2025. The company issued 9,203,000 Units at C$0.05 per Unit, raising gross proceeds of $460,150. Each Unit includes one common share and one half warrant; each full Warrant allows purchase of one common share at C$0.15 and expires in 36 months. The warrant expiry may be accelerated if the 10-day VWAP reaches $0.30 after the four-month hold period. Insiders subscribed $60,000 of the tranche, and all securities are subject to a statutory hold of four months and one day.

Predictmedix said the financing follows recent European investor outreach, including participation at the 25th MK Investment Conference in Munich.

Predictmedix AI (CSE: PMED; OTC Pink: PMEDF) announced a proposed non‑brokered private placement to issue up to 18,000,000 units at C$0.05 per unit for gross proceeds up to C$900,000. Each Unit includes one common share and one half warrant; each whole warrant permits purchase of one common share at C$0.15 and expires in 36 months, subject to an acceleration clause if the 4‑month VWAP test exceeds $0.30 for 10 consecutive trading days.

Proceeds are intended to fund the Predictmedix Core AI Engine, clinical trial applications, SmartHealth AI station certification, B2C mobile platform development, and public‑company functions.

Predictmedix AI (OTC:PMEDF) has launched its Clinical-Trial AI Platform, an advanced solution targeting the $70 billion clinical trials market. The platform leverages patented technology and data from SmartHealth AI Stations to optimize clinical trial planning and execution.

The platform features an adaptive simulation engine, patient-site optimization, cost modeling, and interactive dashboards. Built on validated data streams from over 500,000 SmartHealth scans with approximately 95% accuracy for vital-sign detection, the system provides real-time analytics and continuous intelligence for pharmaceutical sponsors and CROs.

The company is now preparing to offer private demonstrations and explore paid pilot programs with potential clients in the pharmaceutical industry.

Predictmedix AI (OTC: PMEDF) announced its participation in the upcoming 25th MK Investment Conference in Munich, Germany on October 1, 2025. The company's COO and Co-founder, Dr. Rahul Kushwah, will present their AI-powered health and safety technology solutions to a diverse investor audience.

The conference, hosted by Michael Kott and CM-Equity AG, focuses on AI, Longevity, Tech, and ESG sectors. Dr. Kushwah will showcase Predictmedix's proprietary AI technologies designed for health management, clinical trials, and screening applications, highlighting the company's growth vision and recent achievements.

Predictmedix AI (OTC: PMEDF) has unveiled a strategic expansion plan to transform from a single-product health screening company into a diversified AI health-technology enterprise. The company is developing three key growth platforms: a Clinical-Trial AI Platform targeting a $123.5B market by 2030, SmartHealth AI Stations with 95% accuracy in health screening, and a Consumer Vital-Scanning Mobile Application.

The company's strategy focuses on generating recurring revenue through SaaS subscriptions, Screening-as-a-Service, and consumer subscriptions. Their technology is backed by proprietary AI algorithms and targets the global AI healthcare market, projected to reach $187.7B by 2030 with a 38.6% CAGR from 2025-2030.

Predictmedix AI (OTC: PMEDF) announced its expansion into mobile diagnostics with a new AI-powered diabetes screening platform, initially targeting the Indian market. The platform enables non-invasive diabetic screening through smartphones, leveraging facial and biometric analysis technology.

The solution aims to address India's growing diabetes epidemic, where over 100 million people have diabetes and projections indicate nearly 1 in 3 adults will be diabetic or prediabetic by 2045. The platform features instant diabetic risk scoring, multilingual support, and secure data handling compliant with India's DPDP Act.

With India's smartphone user base exceeding 1.1 billion, the company plans to generate recurring revenue through both direct-to-consumer and B2B channels, with potential for global scalability.

Predictmedix AI (PMEDF) has formed a strategic alliance with Pacific Mechatronics to deploy its AI-powered Smart Health Stations across the Asia-Pacific defence sector. The partnership targets key markets including Singapore, Indonesia, Malaysia, the Philippines, and Vietnam.

The Smart Health AI Stations provide automated, contactless health screening using AI and multispectral imaging to detect fatigue, infectious diseases, cognitive impairment, and mental health anomalies. Pacific Mechatronics will lead deployment, integration, and support of these systems at border control zones, military installations, naval docks, and air command units.

The collaboration provides Predictmedix with direct access to defence ministries and aerospace buyers, enabling subscription-based revenue through licenses, maintenance, and upgrades. This expansion represents a parallel growth track alongside the company's North American operations.

Predictmedix AI (PMEDF) announces its participation in an exclusive European investor roadshow across three cities from May 17-21, 2025. The company will be showcasing its AI-driven health and safety solutions in Budapest (May 17), Zagreb (May 19), and Belgrade (May 21).

The roadshow follows recent investments from German family offices and aims to expand the company's European shareholder base. Predictmedix will highlight its Smarthealth AI stations, focusing on workplace safety, healthcare, and public event screening applications.

Additionally, the company has issued 850,000 common shares to a senior technology consultant and settled a debt of $64,806.45 through the issuance of 1,150,000 additional common shares, both subject to a four-month hold period.